Prevalence of Biofilms and Their Response to Medical Treatment in Chronic Rhinosinusitis without Polyps

Basit Öğe Kaydı
dc.authoridCelik, Hakan Hamdi/0000-0002-7909-7604
dc.contributor.authorTatar, Emel Cadalli
dc.contributor.authorTatar, Ilkan
dc.contributor.authorOcal, Bulent
dc.contributor.authorKorkmaz, Hakan
dc.contributor.authorSaylam, Guleser
dc.contributor.authorOzdek, Ali
dc.contributor.authorCelik, Hakan Hamdi
dc.date.accessioned2024-09-29T16:05:00Z
dc.date.available2024-09-29T16:05:00Z
dc.date.issued2012
dc.departmentKarabük Üniversitesien_US
dc.description.abstractObjective. The aim of this study was to investigate the prevalence of biofilms and the effects of medical treatment modalities in chronic rhinosinusitis (CRS) patients without nasal polyps. Study Design. Randomized controlled trial. Settings. Tertiary referral hospital. Subjects and Methods. The authors randomly divided 32 adult patients with CRS without nasal polyps into 2 groups. In the first group (n = 16), oral clarithromycin was administered 500 mg/bid for 2 weeks and then 250 mg/d for the following 6 weeks. In the second group (n = 16), an 8-week course of 200-mcg/d topical mometasone furoate was added to the clarithromycin regimen, identical to the first group. The pre-and posttreatment nasal tissue samples were evaluated by scanning electron microscopy for biofilm prevalence and graded from 0 to 3 according to density and extension. Results. Biofilms were detected in 24 of 32 patients (75%) before the treatment (grades 1-3). Biofilms were detected in 14 of 32 patients (43.8%) after the treatment (grades 12). When each group was evaluated independently, there was a significant improvement after the treatment in both groups I and II. When the biofilm grades of group I were compared to those of group II, there was no significant difference both in the pre-and posttreatment evaluation. Conclusion. The prevalence of biofilms in CRS without polyps was 75% in our study. Regression of biofilms to 43% was observed under medical treatment. Adding nasal steroids to macrolides gave no further benefit.en_US
dc.identifier.doi10.1177/0194599811434101
dc.identifier.endpage675en_US
dc.identifier.issn0194-5998
dc.identifier.issn1097-6817
dc.identifier.issue4en_US
dc.identifier.pmid22241786en_US
dc.identifier.scopus2-s2.0-84861712913en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage669en_US
dc.identifier.urihttps://doi.org/10.1177/0194599811434101
dc.identifier.urihttps://hdl.handle.net/20.500.14619/6430
dc.identifier.volume146en_US
dc.identifier.wosWOS:000303546600029en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofOtolaryngology-Head and Neck Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchronic rhinosinusitisen_US
dc.subjectbiofilmen_US
dc.subjectscanning electron microscopyen_US
dc.subjectclarithromycinen_US
dc.subjectnasal steroiden_US
dc.titlePrevalence of Biofilms and Their Response to Medical Treatment in Chronic Rhinosinusitis without Polypsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu